Command Palette

Search for a command to run...

Clinical Trials · NCT01507311

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

CompletedPhase 1Liraglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
11
Start date
Sep 1999
Locations
1 site, Denmark
Primary endpoint
Insulin secretory burst mass
View Liraglutide compound reference